| Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
HR (range) | P-value | HR (range) | P-value | |
OS | ||||
 Age | 1.020 (1.001–1.039) | 0.034 | 1.015 (0.996–1.035) | 0.121 |
 Dose escalation | 0.472 (0.259–0.858) | 0.014 | 0.494 (0.269–0.906) | 0.023 |
 Localization | 1.064 (0.924–1.225) | 0.387 |  |  |
 Resection status | 1.338 (1.009–1.772) | 0.043 | 1.369 (1.035–1.811) | 0.028 |
 No Temozolomide | 1.421 (0.624–3.232) | 0.403 |  |  |
 RPA Class | 1.183 (0.982–1.424) | 0.077 |  |  |
 PTV (ml) | 1.000 (0.999–1.001) | 0.542 |  |  |
ICC | ||||
 Age | 1.007 (0.991–1.023) | 0.423 |  |  |
 Dose escalation | 0.512 (0.302–0.866) | 0.013 | 0.498 (0.294–0.844) | 0.010 |
 Localization | 1.124 (0.976–1.295) | 0.105 |  |  |
 Resection status | 1.344 (1.032–1.750) | 0.028 | 1.365 (1.047–1.780) | 0.021 |
 No Temozolomide | 1.857 (0.866–3.983) | 0.112 |  |  |
 RPA | 1.062 (0.891–1.267) | 0.502 |  |  |
 PTV (ml) | 1.000 (1.000–1.001) | 0.304 |  |  |